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Abstract
Background: Evidence from epidemiological, clinical and animal studies suggests a link may exist between low
bone density and cardiovascular disease, with inflammatory mediators implicated in the pathophysiology of both
conditions. This project examined whether supplementation with soy isoflavones (IF), shown to have anti-
inflammatory properties, could prevent tissue expression of TNF-α and the development of skeletal pathology in
an animal model of chronic inflammation.
Methods: Eight-week old, intact, female C57BL/6J mice were used. In Phase 1, a lipopolysaccharide (LPS)-dose
response study (0, 0.133, 1.33 and 13.3 µg/d) was conducted to determine the LPS dose to use in Phase 2. The
results indicated the 1.33 µg LPS/d dose produced the greatest decrease in lymphocytes and increase in
neutrophils. Subsequently, in Phase 2, mice were randomly assigned to one of six groups (n = 12–13 per group):
0 or 1.33 µg LPS/d (placebo or LPS) in combination with 0, 126 or 504 mg aglycone equivalents of soy IF/kg diet
(Control, Low or High dose IF). Mice were fed IF beginning 2 wks prior to the 30-d LPS study period.
Results: At the end of the study, no differences were detected in final body weights or uterine weights. In terms
of trabecular bone microarchitecture, µCT analyses of the distal femur metaphysis indicated that LPS significantly
decreased trabecular bone volume (BV/TV) and number (TbN), and increased separation (TbSp). Trabecular bone
strength (i.e. total force) and stiffness were also compromised in response to LPS. The High IF dose provided
protection against these detrimental effects on microarchitecture, but not biomechanical properties. No
alterations in trabecular thickness (TbTh), or cortical bone parameters were observed in response to the LPS or
IF. Immunohistomchemical staining showed that tumor necrosis factor (TNF)-α was up-regulated by LPS in the
endothelium of small myocardial arteries and arterioles as well as the tibial metaphysis and down-regulated by IF.
Conclusion: These results suggest IF may attenuate the negative effects of chronic inflammation on bone and
cardiovascular health. Additional research is warranted to examine the anti-inflammatory properties of the soy
isoflavones and the mechanisms underlying their prevention of chronic inflammation-induced bone loss.
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Background
Osteopenia is a common complication with conditions
associated with chronic elevation of pro-inflammatory
mediators and has been linked to increased incidence of
cardiovascular morbidity and mortality [1,2]. This associ-
ation between low bone density and vascular disease is
supported by population studies [1-4] and clinical evi-
dence [2,5,6], including the recent observation that cardi-
ovascular disease risk in postmenopausal women
increased relative to the severity of their osteopenia [7].
The relationship between the immune, skeletal and cardi-
ovascular systems is further demonstrated in patients with
autoimmune diseases such as rheumatoid arthritis [8,9]
and lupus erythematosus who experience significant bone
loss and increased risk of cardiovascular disease. In a
recent review, Lessem [10] examined the association
between atherosclerosis and alveolar bone loss and sug-
gested the development of atherosclerotic plaques may be
related to a long-term burden of infection. In a rodent
model of chronic inflammation, we have recently demon-
strated that a 90 day exposure to LPS results in a decrease
in bone density localized to the trabecular bone, pervascu-
lar fibrosis and disruption of the intima in intramural
arteries. This provides further evidence to support a link
among the immune, skeletal and cardiovascular systems.
Thus, the association between reduced bone mass and
increased risk of cardiovascular disease may be due in part
to the presence of a persistent inflammatory state.
The dysregulation of pro- versus anti-inflammatory medi-
ators is characteristic of autoimmune diseases and chronic
infections and has been implicated as a potential mecha-
nism involved in the etiology of skeletal decalcification
and cardiovascular diseases [11-14]. Increased tumor
necrosis factor (TNF)-α expression has been reported in
response to estrogen deficiency which coincides with
increased bone loss and cardiovascular disease risk associ-
ated with menopause [15]. These imbalances in pro- and
anti-inflammatory mediators and the failure to resolve the
inflammatory response can have a significant impact on
the health of an individual [16]. Therefore, intervention
strategies targeting these inflammatory pathways may pre-
vent inflammation-induced concomitant bone and vascu-
lar disease.
Epidemiological studies have demonstrated a reduced
mortality rate due to coronary heart disease in popula-
tions consuming soy [17] and other evidence also suggests
the isoflavones (IF) from soybeans may have anti-inflam-
matory activity in cardiovascular disease [18]. A number
of studies have reported decreases in cytokines and
inflammation with either soy foods or IF [19-21]; how-
ever, other research has not observed beneficial effects of
soy isoflavones on markers of inflammation [22,23]. Gen-
istein, the most abundant IF in soy, is a tyrosine kinase
inhibitor [24] and thus may affect signaling pathways of
immune cells and the subsequent innate and adaptive
immune responses. The evidence related to the osteopro-
tective effects of soy IF on skeletal health has been some-
what equivocal [25,26]. Several animal studies have
demonstrated soy IF prevention of bone loss due to ovar-
ian hormone deficiency in rats [27-30], while others have
not observed this same bone protective response in rats
[26] as well as macaque monkeys [31]. Similarly, the data
on soy IF and bone health from clinical trials have been
variable, but promising. Supplementation with soy IF or
soy containing foods have generally resulted in improved
bone biomarkers [32,33], but had varying effects on bone
density [32,34]. More recently, an association between
soy consumption and fracture risk in early menopausal
women was observed in the Shanghai Women's Health
Study [35].
Based upon the evidence outlined above, soy IF provide a
reasonable dietary intervention to consider in the preven-
tion of chronic inflammation-induced bone loss and car-
diovascular diseases. Though most of the soy IF studies
have focused on either the skeletal or cardiovascular sys-
tems, the ability of soy IF to modulate the underlying
inflammatory response involved in both of these condi-
tions has not been assessed. Therefore, the purpose of this
study was two-fold. First, to determine if increasing levels
of soy IF prevents LPS-induced alterations in bone micro-
architectural and biomechanical properties. Second, to
determine if these effects of soy IF were associated with
alterations in local (bone and heart) expression of the
proinflammatory mediator TNF-α.
Methods
Animals
Eight-week old, intact, female C57BL/6J mice (Charles
River Laboratories) were housed in an environmentally
controlled animal care facility and allowed to acclimate
for 1 wk prior to the start of each experiment. Mice were
fed their respective diets and maintained on deionized
water throughout the entire study period. At the termina-
tion of each study, animals were anesthetized and tail
blood samples collected for the determination of differen-
tial leukocyte counts by manual microscopy from a
peripheral blood smear. The mice were bled via the
descending aorta and bone and heart specimens collected.
Uteri were removed, cleaned of fat tissue and weighed to
determine the presence of an estrogenic effect due to the
soy IF. All animal procedures were conducted under an
animal protocol approved by the Oklahoma State Univer-
sity Institutional Animal Care and Use Committee.
Implantation of slow-release pellets
Lipopolysaccharide (E. coli Serotype 0127:B8; Sigma, St.
Louis, MO) was incorporated into slow-release pelletsJournal of Inflammation 2007, 4:17 http://www.journal-inflammation.com/content/4/1/17
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designed to provide a consistent dose for 30 days (Inno-
vative Research of America, Sarosota, FL) and implanted
using the method of Smith et al [36]. In short, the pellets
were subcutaneously implanted in the dorsal region of the
neck, while the animals were anesthetized with isoflu-
rane.
Experimental design and treatments
This study was conducted in two phases: Phase 1 – a LPS
dose-response study to determine the LPS dose to use in
Phase 2; and, Phase 2 – the effects of soy IF in mice
implanted with the slow-release LPS pellets to simulate
chronic inflammation.
In Phase 1, 4 doses of LPS were used which were chosen
based upon previous research in male Sprague Dawley
rats [36]: 0, 0.133, 1.33, and 13.33 µg LPS/d. Mice (12 per
group) were randomly assigned to treatment groups and
fed a semi-purified diet (AIN-93G) throughout the entire
study.
In Phase 2, a randomized control design with a factorial
arrangement of treatments was used. After acclimation,
mice were fed a semi-purified diet (AIN-93G) for two
weeks and then weighed and randomly assigned to one of
six treatments (n = 12 -13 per group): a placebo (pellet
containing matrix only) or LPS (1.33 µg LPS/d) in combi-
nation with 0, 126 or 504 mg aglycone equivalents of soy
IF/kg diet (0, 200 or 800 mg total IF/kg diet; designated as
control, low or high respectively). The IF were provided as
Prevastein 40 Isoflavone concentrate from Solae Com-
pany (St. Louis, MO) which contained 7.95% daidzein,
16.9% genistein and 0.36% glycitein or a total of 25.2%
IF (expressed as aglycone equivalents). Mice were fed their
respective treatment diets beginning 2 weeks prior to
implantation with either a placebo or LPS pellet and then
remained on their respective treatment diets for the 30-d
LPS challenge period.
Microcomputed tomography (µCT) analysis
The influence of chronic inflammation on trabecular and
cortical bone microarchitecture was assessed at the femur
distal metaphysis and middiaphysis. Each specimen was
scanned using µCT (µCT40, SCANCO Medical, Switzer-
land) beginning at the distal growth plate in the proximal
direction 300 slices (~12 µm/slice) for trabecular bone
analyses followed by a scan of the midshaft region (i.e.
~38 slices) for assessment of cortical parameters [37]. An
integration time of 70 milliseconds per projection was
used for each scan with a rotational step of 0.36 degrees
resulting in a total acquisition time of 150 minutes/sam-
ple. Trabecular bone was analyzed by placing contours
beginning 25 slices from the growth plate to include only
secondary spongiosa within the volume of interest (VOI).
This region included 150 images using 1024 × 1024
matrix resulting in an isotropic voxel resolution of 22
µm3 and the following trabecular bone parameters were
evaluated: bone volume (BV/TV), number (TbN), separa-
tion (TbSp), thickness (TbTh), structure model index
(SMI), connectivity density (Conn Den) and linear atten-
uation (Lin Atten). Cortical analyses were performed by
semi-automatically placing contours on 30 images in the
midshaft region. Cortical thickness, cortical surface, med-
ullary area, and porosity were determined. The operator
conducting the scan analysis was blinded to the treat-
ments associated with the specimen. Coefficients of varia-
tion (CVs) were 2.0% (BV/TV), 1.1% (TbN), 0.66%
(TbTh) and 1.30% (TbSp) for morphometric and 4.6%
(Conn Den) and 2.7% (SMI) for non-metric parameters.
Biomechanical assessment using finite element analyses
Simulated compression testing was performed on the
trabecular VOI generated from the µCT analyses to assess
trabecular bone biomechanical strength at the distal
femur metaphysis. Apparent mechanical properties cho-
sen for each bone included: linear, elastic and isotropic
with a Poisson's ratio of 0.3 and a Young's modulus of
10GPa [38]. Simulated compression testing was per-
formed on the VOI from the scan of each distal metaphy-
sis. The finite element (FE) software package (SCANCO
Medical) was utilized for these analyses and physiological
force, stiffness, size-independent stiffness, and von Mises
stresses were determined.
Immunohistochemical staining
At the time of necropsy, tibia and heart specimens were
excised and immediately placed in 10% neutral-buffered
formalin. To determine the alterations in TNF-α expres-
sion in the myocardium, corresponding vasculature, and
bone, immunohistochemical (IHC) staining was per-
formed. Longitudinal sections of decalcified tibia (7 µm)
were cut from paraffin embedded specimens, mounted
onto Superfrost/Plus slides (Fisher Scientific, Fair Lawn,
NJ) and then rehydrated and washed 3X in PBS/Tween 20
(PBS/T; Sigma, St Louis MO). The bone sections were
processed for immunohistochemistry using R&D Systems
HRP-DAB goat kit. In short, sections were treated with
peroxidase blocking reagent, washed with PBS/T and
blocked with serum blocking reagent. After incubation
with normal serum, sections were treated with Avidin/
Biotin blocking reagents and placed in a humidified
chamber overnight at 4°C with a 1:15 dilution of anti-
mouse TNF-α/TNFSF1A antibody (R&D Systems). Sec-
tions were then washed, incubated with biotinylated sec-
ondary antibody, washed again and incubated with high
sensitivity streptavidin conjugated to HRP (R&D Systems
HRP-DAB goat kit). After rinsing with PBS/T slides were
incubated with DAB chromogen for visualization and
counterstained with Immuno * Master Hematoxylin
(American Master * Tech Scientific, Inc., Lodi, CA). Con-Journal of Inflammation 2007, 4:17 http://www.journal-inflammation.com/content/4/1/17
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trols were incubated with omission of the primary anti-
body.
The myocardial cross-sections of the heart (5 µm) were
processed for immunohistochemistry using UltraVision
LP Detection System HRP Polymer & AEC chromogen kit
(Lab Vision Corporation, Fremont, CA). Sections were
treated with DAKO® Peroxidase Blocking Reagent (DAKO
Corporation, Carpinteria, CA) to inhibit endogenous per-
oxidase activity followed by 4X PBS/T washes. Antigen
retrieval was accomplished by placing slides in 10 mM cit-
rate buffer, pH 6.0 in a steamer and cooled at room tem-
perature. Tissue was blocked according to the
manufacuturer's protocol for 5 minutes at room tempera-
ture and incubated with rabbit polyclonal antibody to
TNF-α (dilution of 1:100; Abcam Inc, Cambridge, MA) at
4°C overnight. Sections were then washed with PBS/T 3X,
incubated at room temperature with primary antibody
enhancer, followed by 4 × washes in PBS/T and incuba-
tion with the HRP polymer. After rinsing with PBS/T,
slides were incubated with AEC chromogen for visualiza-
tion. Counterstaining was carried out with Immuno*
Master Hematoxylin (American Master*Tech Scientific,
Inc., Lodi, CA). Controls were incubated with omission of
the primary antibody.
The amount of TNF-α expression in the bone and myocar-
dial slides was scored by a pathologist who was blinded to
treatments. The amount of cell involvement was deter-
mined using a scale of 0 to 4 with 0 representing no cells
expressing staining; 1 representing 1–15% of cells express-
ing TNF-α; 2 representing 16–25% of cells expressing
TNF-α; 3 representing 26–50% of cells expressing TNF-α;
and, 4 representing > 50% of cells exhibiting TNF-α stain-
ing. The intensity of staining was also determined using a
scale of 1 to 4 with 1 representing the least amount of
staining and 4 representing the greatest amount of stain-
ing. The overall score was calculated by multiplying the
categorical score for cell involvement by the categorical
score for intensity of staining and was used in statistical
analyses. The data for cell involvement and intensity of
staining is expressed as the percent of animals receiving
each score.
Data presentation and statistical analysis
Statistical analysis was performed using PC SAS statistical
software (version 8.02; SAS Institute Inc., Cary, NC). In
Phase I the variables were analyzed by one-way ANOVA
and in Phase II the variables were analyzed by two-way
ANOVA with LPS and IF as factors. The ANOVA analyses
were followed by post hoc analysis using the Fisher's least
squares means separation test when F values were signifi-
cant. Data are presented as means ± standard error (SE).
For all analyses, a p < 0.05 was considered to be signifi-
cantly different.
Results
Phase 1 differential counts
The percentage of lymphocytes was decreased (P < 0.05)
(Placebo = 90.4 ± 2.3, Low = 85.2 ± 1.3, Medium = 75.5 ±
2.5, High = 65.7 ± 9.7) with increasing dose of LPS, while
the percentage of neutrophils was increased (P < 0.05)
from 4.5 ± 1.0 in the placebo group to 7.4 ± 1.9, 15.7 ±
1.5, and 12.0 ± 3.2 in the Low, Medium and High doses,
respectively. Mice receiving the 1.33 µg LPS/d dose experi-
enced the greatest change in the proportion of lym-
phocytes and neutrophils, while mice administered the
highest dose did not show further changes. No differences
(P > 0.05) were observed in the percentages of monocytes,
eosinophils and basophils (data not shown). The three
relatively low doses of LPS utilized in this study produced
no detectable alterations in animal behavior in terms of
grooming, food consumption and physical activity, but
localized edema did develop around the pellet and was
resolved within the first week of the study. Based upon the
lymphocyte and neutrophil data, the medium dose of
1.33 µg LPS/d was chosen to induce the low grade inflam-
matory state to be used in Phase 2.
Phase 2 body weights and uterine weights
As expected, no alterations (P > 0.05) in final body
weights or uterine weights in response to soy IF or LPS
were observed at the end of the study (Table 1). These data
suggest soy IF, even at the high dose, did not have an
estrogenic influence on the young, growing female mice.
The absence of an effect on body weight combined with
no noticeable alterations in food intake or grooming
behavior, confirms our previous observation [36] in
which chronic exposure to LPS at the dose used in the
present study induced a low-grade inflammation but did
not negatively impact basic animal behaviors.
Bone microarchitecture
Alterations in trabecular bone microarchitecture of the
distal femur metaphysis and cortical parameters in the
femur middiaphysis were analyzed using µCT. BV/TV
(Table 2) was reduced (p < 0.05) by LPS in the 0 and low
IF groups, but high IF protected (p < 0.05) against this det-
rimental effect on trabecular bone. As with BV/TV, chronic
exposure to LPS decreased (p < 0.05) the TbN and
increased (p < 0.05) TbSp in the 0 and low IF groups. The
high IF protected (p < 0.05) against this deterioration in
TbN and TbSp associated with chronic LPS administration
(Table 2). TbTh and SMI (Table 2) were unaffected (p >
0.05) by either IF or LPS. Linear x-ray attenuation, indica-
tive of trabecular bone density, tended (p = 0.06) to be
reduced with high IF in the placebo group and enhanced
with high IF under inflammatory conditions (Table 2).
Trabecular bone connectivity density was reduced (p <
0.05) in the absence of LPS with high IF, but under
inflammatory conditions this was not the case (Table 2).Journal of Inflammation 2007, 4:17 http://www.journal-inflammation.com/content/4/1/17
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Cortical bone microarchitecture at the femur mid-diaphy-
sis was also assessed. No alterations in cortical thickness,
cortical area, medullary area or porosity were observed in
conjunction with either LPS or IF at the end of the study
period (Table 3).
Bone biomechanical properties
Data from simulated compression testing demonstrated
the alterations in trabecular bone microarchitecture
induced by the chronic inflammatory conditions had del-
eterious effects on bone biomechanical properties. Total
and physiological compressive forces were significantly
reduced by LPS and bone stiffness was also compromised
(Table 4). Soy IF had no effect on these biomechanical
properties, and even though the higher dose preserved
many of the bone microarchitectural properties it was
unable to protect against the detrimental effects of LPS on
bone strength.
Histopathology
To evaluate localized changes in proinflammatory
cytokines implicated in the etiology of bone loss and car-
diovascular diseases, the expression of TNF-α was evalu-
ated in both bone and heart tissue. Up-regulation of TNF-
α expression was evident in the metaphyseal region of the
tibia after 30 days of exposure to LPS (Figure 1D). As can
been seen in Figure 1E and 1F, both the low and high
doses of IF down-regulated the LPS-induced TNF-α
expression within this region of the bone. Table 5 shows
the cell involvement and the intensity of staining in the
bone tissue. As evidenced by the overall score for TNF-α
expression, both the low and high doses of IF were able to
prevent (P < 0.05) an increase in LPS-induced TNF-α
expression.
Similar results were observed in the myocardium (Figure
2). Chronic exposure (30-d) to LPS increased endothelial
TNF-α expression in the small intramural arteries and
arterioles (Figure 2D) which was down-regulated by the
low and high doses of IF (Figure 2E &2F; Table 6).
Discussion
Administration of LPS has been used extensively in in vitro
and in vivo studies to evaluate the influence of the innate
immune response on the skeletal and cardiovascular sys-
tems. Much of the research has used either a single injec-
tion of LPS to simulate an acute response [39] or repeated
injections [40,41] or infusion [42] to simulate chronic
inflammation; however, few of these models have been
maintained for more than 2 weeks. Recently, Smith et al
[36] utilized a slow-release pellet system impregnated
Table 1: Body and uterine weight in mice fed soy isoflavones and 
administered LPS.
Treatment Body wt (g) Uterine wt (g)
0 IF Placebo 19.0 ± 0.3 0.12 ± 0.01
0 IF LPS 19.6 ± 0.4 0.11 ± 0.01
126 IF Placebo 19.6 ± 0.2 0.12 ± 0.01
126 IF LPS 19.4 ± 0.3 0.13 ± 0.01
504 IF Placebo 19.7 ± 0.3 0.11 ± 0.01
504 IF LPS 19.7 ± 0.2 0.13 ± 0.01
P value
LPS 0.4703 0.1457
IF 0.3844 0.4305
LPS*IF 0.3933 0.2276
Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone 
equivalents of IF/kg diet) for 14-days prior to and during a 30-day 
exposure to LPS (1.33 µg/d). Results are expressed as means ± 
standard error.
Table 2: Alterations in microarchitectural properties of trabecular bone of the femur distal metaphysis.
Treatment BV/TV (%)A TbN 
(1/mm3)B
TbSp (mm)C TbTh (mm)D Conn Den
 (1/mm3)E
SMIF Linear 
Attenuation
0 IF Placebo 8.80 ± 0.01a 3.89 ± 0.15a, c 0.27 ± 0.01a 0.051 ± 0.001 58.97 ± 8.14a 2.63 ± 0.10 1.01 ± 0.02
0 IF LPS 6.34 ± 0.01b 3.25 ± 0.15b 0.32 ± 0.01b, d 0.052 ± 0.001 40.56 ± 8.80a, b 2.83 ± 0.15 0.90 ± 0.06
126 IF 
Placebo
8.80 ± 0.01a 3.92 ± 0.10a 0.26 ± 0.01a 0.050 ± 0.002 47.33 ± 6.72a, b 2.91 ± 0.16 1.01 ± 0.02
126 IF LPS 6.52 ± 0.01b 3.41 ± 0.13b, e 0.30 ± 0.01b, c, d 0.050 ± 0.001 33.56 ± 3.80b 3.02 ± 0.05 0.95 ± 0.02
504 IF 
Placebo
7.14 ± 0.01a, b 3.50 ± 0.17b, c, d 0.29 ± 0.02a, d 0.050 ± 0.001 34.12 ± 4.99b 2.96 ± 0.14 0.96 ± 0.03
504 IF LPS 8.40 ± 0.01a, b 3.71 ± 0.14a, d, e 0.28 ± 0.01a, c 0.053 ± 0.002 52.12 ± 8.87a, b 2.93 ± 0.15 1.00 ± 0.02
P value
LPS 0.0731 0.0085 0.119 0.2834 0.4317 0.3779 0.1018
IF 0.9681 0.7839 0.5918 0.2478 0.4208 0.1493 0.6326
LPS*IF 0.0397 0.0099 0.0124 0.6706 0.0341 0.6773 0.0613
Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone equivalents of IF/kg diet) for 14-days prior to and during a 30-day exposure to LPS 
(1.33 µg/d). Results are expressed as means ± standard error. (A) trabecular bone volume (BV/TV), (B) trabecular number (TbN), (C) trabecular 
separation (TbSp), and (D) trabecular thickness (TbTh), (E) Connective Density (Conn Den), (F) Structure Model Index (SMI). Values for a given 
parameter that share the same superscript letter are not statistically different (P > 0.05) from each other.Journal of Inflammation 2007, 4:17 http://www.journal-inflammation.com/content/4/1/17
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with very low doses of LPS to study the influence of an
inflammatory state over 90 days on bone metabolism,
myocardial and vascular pathology in male Sprague Daw-
ley rats. Continuous administration of LPS produced a
persistent systemic inflammatory state characterized by
up-regulation of proinflammatory molecules in bone and
the vascular endothelium of the heart with concurrent
trabecular bone loss. This same technique of administer-
ing LPS was used in the present study over 30 days in
female mice in which we also observed up-regulation of
the proinflammatory cytokine, TNF-α in bone and vascu-
lar tissue at 30 days. This further supports the presence of
an ongoing chronic inflammatory state without altera-
tions in animal behavior, suggestive of a very low grade
inflammatory response.
In the present study, the LPS-induced inflammation in
mice resulted in reduced trabecular bone characterized by
a decrease in the number of trabeculae and an increase in
the inter-trabecular space with subsequent decreases in
bone biomechanical properties. An increase in TNF-α
expression in trabecular bone was also observed with LPS
administration suggesting a role for this cytokine in bone
loss. Tumor necrosis factor-α stimulates osteoclast differ-
entiation and activity resulting in an increase in bone
resorption [43] and inhibits bone formation by decreas-
ing osteoblast progenitor cell recruitment and increasing
osteoblast apoptosis [40,41]. The alterations in bone
combined with the myocardial and vascular changes
induced by low grade inflammation provide further sup-
port for the theory that inflammatory mediators provide
the pathophysiological link between these two disease
processes. Interventions targeting changes in local proin-
flammatory cytokine expression and circulating leuko-
cytes are thus warranted [39,44] in order to prevent the
detrimental effects of chronic inflammation.
A variety of in vitro, in vivo and clinical studies have sug-
gested that dietary soy isoflavones have anti-inflamma-
tory properties thus potentially influencing
inflammation-induced bone loss and vascular changes.
The effects of soy IF on circulating proinflammatory
Table 3: Alterations in microarchitectural properties of cortical bone of the femur mid-diaphysis.
Treatment Cortical Thickness 
(µm)
Cortical Area (mm2) Medullary Area (mm2) Porosity (%)
0 IF Placebo 0.187 ± 0.003 0.625 ± 0.001 0.010 ± 0.001 0.98 ± 0.28
0 IF LPS 0.197 ± 0.003 0.646 ± 0.010 0.010 ± 0.002 0.84 ± 0.20
126 IF Placebo 0.193 ± 0.002 0.628 ± 0.014 0.009 ± 0.001 1.07 ± 0.22
126 IF LPS 0.191 ± 0.003 0.625 ± 0.008 0.012 ± 0.002 1.08 ± 0.31
504 IF Placebo 0.194 ± 0.005 0.625 ± 0.014 0.010 ± 0.001 0.99 ± 0.24
504 IF LPS 0.198 ± 0.001 0.652 ± 0.011 0.009 ± 0.001 0.86 ± 0.22
P value
LPS 0.1340 0.1086 0.4386 0.6895
IF 0.4189 0.5571 0.5553 0.7637
LPS*IF 0.1293 0.3899 0.1988 0.9444
Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone equivalents of IF/kg diet; 0, Low or High, respectively) for 14-days prior to and during 
a 30-day exposure to LPS (1.33 µg/d). Results are expressed as means ± standard error.
Table 4: Biomechanical properties of trabecular bone in the distal femur.
Treatment Total Force (N) Physiological Force 
(N)
Stiffness 
(N/m × 103)
Size Independent 
Stiffness (N/m2)
Von Mises Stress 
(MPa)
0 IF Placebo 272.51 ± 33.62a 81.75 ± 10.09a 435.24 ± 52.46a 309.18 ± 36.02a 15.49 ± 1.41a
0 IF LPS 173.95 ± 56.94b 52.19 ± 17.08b 277.19 ± 90.74b 183.87 ± 58.53b 35.94 ± 10.22b
126 IF Placebo 272.43 ± 68.25a 81.73 ± 20.47a 432.74 ± 107.88a 299.34 ± 72.88a 25.75 ± 9.86a
126 IF LPS 111.29 ± 16.51b 33.39 ± 5.00b 177.58 ± 26.20b 128.93 ± 21.01b 32.19 ± 5.46b
504 IF Placebo 205.29 ± 40.16a 61.59 ± 12.05a 327.76 ± 64.41a 235.51 ± 46.35a 26.54 ± 8.11a
504 IF LPS 214.20 ± 65.75b 64.26 ± 17.73b 340.86 ± 104.08b 251.69 ± 78.52b 29.92 ± 7.83b
P-values
LPS 0.0500 0.0500 0.0487 0.0500 0.1617
IF 0.8232 0.8232 0.8144 0.8148 0.8431
LPS*IF 0.2475 0.2475 0.2497 0.2388 0.9095
Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone equivalents of IF/kg diet) for 14-days prior to and during a 30-day exposure to LPS 
(1.33 µg/d). Biomechanical properties were determined using simulated compression strength testing with finite element analysis. Results are 
expressed as means ± standard error. Values for a given parameter that share the same superscript letter are not statistically different (P > 0.05) 
from each other.Journal of Inflammation 2007, 4:17 http://www.journal-inflammation.com/content/4/1/17
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cytokines, such as TNF-α, have been inconsistent which is
likely due to differences in the amount and type of soy
product consumed and the length of the study [45-47].
The discrepancies in the clinical findings may suggest the
existence of a threshold IF concentration which is needed
before beneficial effects will be observed. The beneficial
effects of soy IF on proinflammatory cytokines may also
be most relevant when mediated at the tissue level. In the
present study, the LPS-induced TNF-α expression in vas-
cular and bone tissue was down-regulated with IF. These
observations suggest the IF may aid in the resolution of
inflammation [48] at the tissue level thus averting the det-
rimental consequences of inflammation-induced bone
loss and vascular changes that can lead to cardiovascular
diseases.
Numerous pre-clinical and clinical studies have evaluated
the ability of soy and its IF to retard or reverse bone loss
with varied results [25,26,49]. In the present study, the
high dose of IF (504 mg IF/kg diet) was able to protect
against the deterioration of trabecular bone microarchi-
tectural properties observed with chronic LPS administra-
tion. These effects may have been mediated to some
degree by soy IF's ability to protect against the TNF-α-
induced increase in osteoclast differentiation and activity,
inhibition of osteoblast activity or perhaps both [50]. Fur-
thermore, soy IF may also inhibit TNF-α-induced apopto-
sis in osteoblasts [51]. Despite the improvement in
trabecular bone, it should be noted that in the present
study soy IF were not able to completely protect against
the harmful effects of inflammation on trabecular bone
biomechanical properties as demonstrated by the simu-
lated compression testing using finite element analysis.
Although these data represent dissociation between
trabecular microarchitecture and bone strength, it is
unclear as to whether some intrinsic tissue quality was
altered by chronic inflammation that could not be pre-
vented by soy IF or if the short duration of the study was
a determining factor. It should also be noted that the
higher dose of IF (504 mg IF/kg diet) tended to reduce the
trabecular bone microarchitectural properties of connec-
tive density and linear attenuation suggesting a detrimen-
tal effect of the higher IF concentrations on trabecular
Table 5: TNF-α expression in bone
Score Cells Expressing TNF-α Intensity of TNF-α Expression Overall Score* 
(Cells Expressing × Intensity of 
Expression)
%%
0 IF Placebo 1 0 2.0 ± 0.3 0 2.0 ± 0.0 5.0 ± 0.6b
2 50 100
35 0 0
40 0
126 IF Placebo 1 33.3 1.7 ± 0.3 100 1.0 ± 0.0 1.7 ± 0.3c
26 6 . 6 0
30 0
40 0
504 IF Placebo 1 33.3 1.7 ± 0.3 100 1.0 ± 0.0 1.7 ± 0.3c
26 6 . 6 0
30 0
40 0
0 IF LPS 1 0 4.0 ± 0.0 0 4.0 ± 0.0 16.0 ± 0.0a
20 0
30 0
4 100 100
126 IF LPS 1 33.3 1.3 ± 0.3 33.3 1.7 ± 0.3 2.0 ± 0.0c
2 66.6 66.6
30 0
40 0
504 IF LPS 1 100 1.0 ± 0.0 33.3 1.7 ± 0.3 1.7 ± 0.3c
20 6 6 . 6
30 0
40 0
Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone equivalents of IF/kg diet) for 14-days prior to and during a 30-day exposure to LPS (1.33 
µg/d). TNF-α expression was determined immunhistochemically. Chi-square analysis was performed on the % of cells expressing TNF-α and the 
intensity of expression. The overall score was calculated. Results for the overall score are expressed as means ± standard error. Values for a given 
parameter that share the same superscript letter are not statistically different (P > 0.05) from each other. P-value for LPS*Diet on overall scores is < 
0.0001.
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bone. These observations warrant further investigation
due to the prevalent usage of IF supplements.
Our results suggest that by down-regulating inflammatory
mediators such as TNF-α at the tissue level, soy IF may
reduce the risk of cardiovascular diseases associated with
chronic inflammation. However, it should be mentioned
that the results of clinical trials have been mixed at best
and it is unclear whether the benefits associated with soy
are due to its isoflavones, fat, fiber or micronutrient con-
tent [52]. Whether soy IF's ability to reduce systemic levels
of pro-inflammatory cytokines [45] or localized tissue
expression as evidenced in the present study translates
into cardiovascular disease risk reduction remains to be
determined. Further studies are warranted to clarify
whether it is the effects of soy IF on TNF-α alone or other
inflammatory pathways that mediate these protective
effects on bone and cardiovascular tissue.
Conclusion
Administration of LPS over 30 days using a slow-release
pellet system produced a low grade chronic inflammation
in mice that resulted in bone pathology and increased tis-
sue expression of TNF-α. Dietary supplementation with
soy IF was able to avert the detrimental effects of chronic
inflammation on the skeletal system. This protection pro-
vided by soy IF occurred in conjunction with down-regu-
Tumor-necrosis-α expression in proximal tibia metaphysis Figure 1
Tumor-necrosis-α expression in proximal tibia metaphysis. Micrographs (20x) from immunohistochemical staining for 
TNF-α in the proximal tibia metaphysis of mice following the feeding of soy isoflavones (IF; 0, 126 or 504 mg aglycone equiva-
lents of IF/kg diet) for 14-days prior to and during a 30-day exposure to LPS (1.33 µg/d). Tibial sections shown are from mice 
administered: 0 LPS (placebo pellets) with either (A) 0 IF, (B) low IF (126 mg IF/kg diet), or (C) high IF (504 mg IF/kg diet); or 
LPS (pellets releasing 1.33 µg/d) with either (D) 0 IF, (E) low IF (126 mg IF/kg diet), or (F) high IF (504 mg IF/kg diet). The rep-
resentative sections demonstrate an increase in expression of TNF-α with LPS (arrow in D) and a down-regulation of expres-
sion with the low (E) and high (F) IF doses.
 F. E. D.
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lating TNF-α expression in both bone and vascular tissue
suggesting that TNF-α may serve as a key link between the
concomitant bone loss and development of cardiovascu-
lar disease in conditions of chronic inflammation. Further
research is needed to delineate the mechanism(s) under-
lying the effects of soy IF on TNF-α as well as other inflam-
matory mediators.
Abbreviations
ANOVA – analysis of variance
BV/TV – trabecular bone volume
IF – isoflavones
LPS – lipopolysaccharide
TbN – trabecular number
TbSp – trabecular spacing
TbTh – trabecular thickness
TNF-α – tumor necrosis factor-α
Tumor-necrosis-α expression in myocardial tissue Figure 2
Tumor-necrosis-α expression in myocardial tissue. Representative cross-sections of the myocardium showing immuno-
histochemical staining for TNF-α in mice administered: 0 LPS (placebo pellets) with either (A) 0 IF, (B) low IF (126 mg IF/kg 
diet), or (C) high IF (504 mg IF/kg diet); or LPS (pellets releasing 1.33 µg/d) with either (D) 0 IF, (E) low IF (126 mg IF/kg diet), 
or (F) high IF (504 mg IF/kg diet). Micrographs (20x) show no endothelial expression of TNF-α in the placebo mice but a 
marked increase in the animals receiving LPS (note arrows indicating TNF-α expression). TNF-α expression was down-regu-
lated with increasing dose of IF.
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